Ken Sugimoto    Department   Kawasaki Medical School  Kawasaki Medical School, Department of General Geriatric Medicine,    Position   Professor
Article types	原著
Language	English
Peer review	Peer reviewed
Title	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial.
Journal	Formal name：NPJ aging and mechanisms of disease Abbreviation：NPJ Aging Mech Dis ISSN code：20563973/20563973
Domestic / Foregin	Foregin
Volume, Issue, Page	4,pp.2
Author and coauthor	Nakagami Hironori, Sugimoto Ken, Ishikawa Takahiro, Fujimoto Taku, Yamaoka Toshifumi, Hayashi Misa, Kiyohara Eiji, Ando Hiroshi, Terabe Yuta, Takami Yoichi, Yamamoto Koichi, Takeya Yasushi, Takemoto Minoru, Koshizaka Masaya, Ebihara Tamotsu, Nakamura Ayumi, Nishikawa Mitsunori, Yao Xiang Jing, Hanaoka Hideki, Katayama Ichiro, Yokote Koutaro, Rakugi Hiromi
Publication date	2018/02
Summary	SR-0379 is a functional peptide that has wound healing effect with anti-microbial action, making it an ideal drug to prevent infection. To evaluate the safety, efficacy, and pharmacokinetics of SR-0379 for the treatment of leg ulcers, a physician-initiated, phase I/IIa, first-in-patient clinical study was designed. A multi-center, double-blind, randomized clinical study was conducted from October 2015 to September 2016. The inclusion criteria for leg ulcers were (1) diabetes or critical limb ischemia and (2) wound size <6 cm in diameter. Twelve patients were randomized into four groups and administered 0.02%, 0.1%, or 0.5% SR-0379 or placebo treatment on skin ulcers once per day for 28 days. Efficiency was evaluated by determining the rate of wound size reduction as a primary endpoint at 4 weeks after the first treatment compared with the pre-treatment wound size. As a secondary endpoint, the DESIGN-R score index, time to wound closure, and the 50% wound size reduction ratio were also evaluated. The safety of SR-0379 was evaluated during the study period. In the evaluation of efficiency, the skin ulcer reduction rates at the last evaluation were 44.73% for the 0.02% SR-0379 group, 68.25% for the 0.1% group, and 71.61% for the 0.5% group, compared with 9.95% for the placebo group. Six adverse events were reported in four patients, of which one occurred in the placebo group, and causal relationships to study drugs were denied for all six events. Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective.
DOI	10.1038/s41514-018-0021-7
PMID	29449960